A detailed history of Paradigm Biocapital Advisors LP transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 5,503,600 shares of OLMA stock, worth $33.6 Million. This represents 2.37% of its overall portfolio holdings.

Number of Shares
5,503,600
Previous 7,903,600 30.37%
Holding current value
$33.6 Million
Previous $85.5 Million 23.16%
% of portfolio
2.37%
Previous 3.46%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.41 - $16.46 $25 Million - $39.5 Million
-2,400,000 Reduced 30.37%
5,503,600 $65.7 Million
Q4 2023

Feb 14, 2024

BUY
$10.53 - $17.14 $1.05 Million - $1.71 Million
100,000 Added 1.28%
7,903,600 $111 Million
Q3 2023

Nov 14, 2023

BUY
$8.19 - $12.98 $33.4 Million - $52.9 Million
4,072,554 Added 109.15%
7,803,600 $96.4 Million
Q2 2023

Aug 14, 2023

BUY
$3.22 - $9.65 $4.34 Million - $13 Million
1,348,669 Added 56.61%
3,731,046 $33.7 Million
Q1 2023

May 15, 2023

BUY
$2.55 - $4.97 $6.08 Million - $11.8 Million
2,382,377 New
2,382,377 $8.27 Million

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $247M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.